Selander KS - Search Results

1

Calcitonin promotes osteoclast survival in vitro.

Selander KS, Härkönen PL, Valve E, Mönkkönen J, Hannuniemi R, Väänänen HK. Selander KS, et al. Mol Cell Endocrinol. 1996 Sep 18;122(2):119-29. doi: 10.1016/0303-7207(96)03870-1. Mol Cell Endocrinol. 1996. PMID: 8902842

2

CD73 regulates zoledronate-induced lymphocyte infiltration in triple-negative breast cancer tumors and lung metastases.

Petruk N, Siddiqui A, Tadayon S, Määttä J, Mattila PK, Jukkola A, Sandholm J, Selander KS. Petruk N, et al. Among authors: selander ks. Front Immunol. 2023 Jul 18;14:1179022. doi: 10.3389/fimmu.2023.1179022. eCollection 2023. Front Immunol. 2023. PMID: 37533856 Free PMC article.

3

The effects of bisphosphonates on the resorption cycle of isolated osteoclasts.

Selander K, Lehenkari P, Väänänen HK. Selander K, et al. Calcif Tissue Int. 1994 Nov;55(5):368-75. doi: 10.1007/BF00299317. Calcif Tissue Int. 1994. PMID: 7532540

4

Characteristics of clodronate-induced apoptosis in osteoclasts and macrophages.

Selander KS, Mönkkönen J, Karhukorpi EK, Härkönen P, Hannuniemi R, Väänänen HK. Selander KS, et al. Mol Pharmacol. 1996 Nov;50(5):1127-38. Mol Pharmacol. 1996. PMID: 8913344

5

Short-term intravenous bisphosphonates in prevention of postmenopausal bone loss.

Heikkinen JE, Selander KS, Laitinen K, Arnala I, Väänänen HK. Heikkinen JE, et al. Among authors: selander ks. J Bone Miner Res. 1997 Jan;12(1):103-10. doi: 10.1359/jbmr.1997.12.1.103. J Bone Miner Res. 1997. PMID: 9240732 Free article. Clinical Trial.

6

Alendronate disturbs vesicular trafficking in osteoclasts.

Alakangas A, Selander K, Mulari M, Halleen J, Lehenkari P, Mönkkönen J, Salo J, Väänänen K. Alakangas A, et al. Calcif Tissue Int. 2002 Jan;70(1):40-7. doi: 10.1007/s002230010047. Epub 2001 Dec 21. Calcif Tissue Int. 2002. PMID: 11907706

7

Tumor necrosis factor-alpha induces interleukin-6 production via extracellular-regulated kinase 1 activation in breast cancer cells.

Suarez-Cuervo C, Harris KW, Kallman L, Väänänen HK, Selander KS. Suarez-Cuervo C, et al. Among authors: selander ks. Breast Cancer Res Treat. 2003 Jul;80(1):71-8. doi: 10.1023/a:1024443303436. Breast Cancer Res Treat. 2003. PMID: 12889600

8

Bisphosphonate induced growth inhibition of breast cancer cells is augmented by p38 inhibition.

Merrell M, Suarez-Cuervo C, Harris KW, Väänänen HK, Selander KS. Merrell M, et al. Among authors: selander ks. Breast Cancer Res Treat. 2003 Oct;81(3):231-41. doi: 10.1023/a:1026126430905. Breast Cancer Res Treat. 2003. PMID: 14620918

9

Breast cancer cells with inhibition of p38alpha have decreased MMP-9 activity and exhibit decreased bone metastasis in mice.

Suarez-Cuervo C, Merrell MA, Watson L, Harris KW, Rosenthal EL, Väänänen HK, Selander KS. Suarez-Cuervo C, et al. Among authors: selander ks. Clin Exp Metastasis. 2004;21(6):525-33. doi: 10.1007/s10585-004-3503-x. Clin Exp Metastasis. 2004. PMID: 15679050

10

Serum TRACP 5b and ICTP as markers of bone metastases in breast cancer.

Korpela J, Tiitinen SL, Hiekkanen H, Halleen JM, Selander KS, Väänänen HK, Suominen P, Helenius H, Salminen E. Korpela J, et al. Among authors: selander ks. Anticancer Res. 2006 Jul-Aug;26(4B):3127-32. Anticancer Res. 2006. PMID: 16886645 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

55 results

Search Page

Filters